[en] A standardised risk assessment before initiating ICI treatment may improve early detection and management of IR-ILD. Multidisciplinary collaboration is crucial for enhancing patient safety, improving treatment outcomes and advancing research. https://bit.ly/4qAthl6.
Disciplines :
Oncology
Author, co-author :
Fabbri, Laura ; National Heart and Lung Institute, Imperial College London, London, UK ; Department of Respiratory Medicine, Royal Brompton Hospital, London, UK
Antoniou, Katerina; Department of Respiratory Medicine, and Laboratory of Molecular and Cellular Pneumonology, School of Medicine, University of Crete, Heraklion, Greece
Blum, Torsten Gerriet ; Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany ; Medical School Berlin, Berlin, Germany
Camus, Philippe; Service de Pneumologie et Soins Intensifs Respiratoires, Hopital du Bocage Centre Hospitalier Universitaire (CHU) de Bourgogne, Dijon, France ; UFR des Sciences de Santé, Université de Bourgogne, Dijon, France ; Faculté de Médecine, INSERM U866, Dijon, France, Paris, France
Cazes, Aurélie; Department of Pathology, Bichat hospital, Assistance Publique-Hôpitaux de Paris
Chorostowska-Wynimko, Joanna ; Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland
Foidart, Pierre ; Université de Liège - ULiège ; Université de Liège - ULiège > Département des sciences cliniques > Oncologie Médicale
Hardavella, Georgia; Department of Respiratory Medicine, "Sotiria" Athens' Chest Diseases Hospital, Athens, Greece
Heuvelmans, Marjolein A; Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands ; Institute for Diagnostic Accuracy, Groningen, Netherlands ; Department of Respiratory Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands
Karampitsakos, Theodoros ; Division of Pulmonary, Critical Care and Sleep Medicine, Ubben Center for Pulmonary Fibrosis Research, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL, USA
Kreuter, Michael; Lung Center Mainz, Mainz, Department of Pneumology, Mainz University Medical Center, and Department of Pulmonary, Critical Care and Sleep Medicine, Marienhaus Clinic Mainz, Mainz, Germany
Pereira Catarata, Maria Joana; Pulmonology Department, ULS Braga, Braga, Portugal ; Tumour and Microenvironment Interactions Group, I3S-Institute for Health Research and Innovation, University of Porto, Porto, Portugal
Naidoo, Jarushka; Department of Oncology, Beaumont Hospital, Beaumont RCSI Cancer Centre, Dublin, Ireland ; RCSI University of Health Sciences, Dublin, Ireland
Passaro, Antonio; Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy
Prosch, Helmut ; Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
Russell, Anne-Marie ; University of Birmingham, Birmingham, UK
Tarnoki, David Laszlo; Department of Medical Imaging, Semmelweis University, Budapest, Hungary
Porter, Joanna C ; UCL Respiratory, Faculty of Medical Sciences, University College London Division of Medicine, London, UK ; Interstitial Lung Disease Service, University College London Hospitals NHS Foundation Trust, UCLH Biomedical Research Centre, NIHR Respiratory-TRC, and UK ILD-National Research Strategy Group, London, UK ; These authors contributed equally
Guiot, Julien ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie ; These authors contributed equally
Spagnolo P, Chaudhuri N, Bernardinello N, et al. Pulmonary adverse events following immune checkpoint inhibitors. Curr Opin Pulm Med 2022; 28: 391–398.
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443–2454.
Haanen J, Obeid M, Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217–1238.
Matsumoto K, Shiroyama T, Kuge T, et al. Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: A systematic review and meta-analysis of cohort studies. Transl Lung Cancer Res 2022; 11: 1835–1846.
Camus P. Pneumotox v 2.2 The Drug-Induced Respiratory Disease Website. Date last accessed: 31 March 2025. www.pneumotox.com/drug/index/
Distefano G, Fanzone L, Palermo M, et al. HRCT patterns of drug-induced interstitial lung diseases: A review. Diagnostics 2020; 10: 244.
Yin Q, Wu L, Han L, et al. Immune-related adverse events of immune checkpoint inhibitors: A review. Front Immunol 2023; 14: 1167975.
Nobashi TW, Nishimoto Y, Kawata Y, et al. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers. Br J Radiol 2020; 93: 20200409.
Pérez Pérez JL, Gayá García-Manso I, García Sevila R. Acute fibrinous and organizing pneumonia associated with immunotherapy (pembrolizumab). Arch Bronconeumol 2022; 58: 425–426.
Smith DA, Radzinsky E, Tirumani SH, et al. Findings on chest CT performed in the emergency department in patients receiving immune checkpoint inhibitor therapy: Single-institution 8-year experience in 136 patients. Am J Roentgenol 2021; 217: 613–622.
Yamazaki M, Watanabe S, Tominaga M, et al. (18)F-FDG-PET/CT uptake by noncancerous lung as a predictor of interstitial lung disease induced by immune checkpoint inhibitors. Acad Radiol 2025; 32: 1026–1035.
